Skip to main content
Fig. 9 | The Journal of Headache and Pain

Fig. 9

From: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies

Fig. 9

Proportion of PGIC responders in participants aged ≥60 years and the overall population. PGIC, patient global impression of change. Data shown are the proportion of PGIC responders (defined as individuals who reported a rating of 5–7 [moderately better, better, or a great deal better] on the PGIC) at Week 12. aP < 0.01 vs placebo. bP < 0.005 vs placebo. cP < 0.0001 vs placebo

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us